Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
Ernexa Therapeutics Inc. (ERNA)
Company Research
Source: GlobeNewswire
Access the “What This Means” segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor "What This Means" segment discussing the Company’s recent successful Pre-IND meeting with the U.S. Food and Drug Administration and its continued advancement toward a first-in-human trial for ovarian cancer. As part of the segment, Sanjeev Luther, President & CEO of Ernexa, highlighted how regulatory alignment from the FDA on Ernexa’s development strategy for its lead cell therapy, ERNA-101, provides a clear pathway toward submitting an Investigational New Drug application and initiating clinical testing in the second half of 2026. This reinforces that technology transfer for clinical-grade manufacturing is already underway, accelerating operational readiness and positionin
Show less
Read more
Impact Snapshot
Event Time:
ERNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ERNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ERNA alerts
High impacting Ernexa Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ERNA
News
- Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration ProgramGlobeNewswire
- Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian CancerGlobeNewswire
- Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian CancerGlobeNewswire
- Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual MeetingGlobeNewswire
- Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOGGlobeNewswire
ERNA
Sec Filings
- 2/3/26 - Form S-1
- 12/19/25 - Form SCHEDULE
- 12/16/25 - Form SCHEDULE
- ERNA's page on the SEC website